Mice with CML who were given a synthetic version of miR-142 lived much longer and were even cured. Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma. Hematological cancer and death by hematological cancer was reduced in the group that had undergone bariatric surgery. Anne Sophie Kubasch, MD, of Leipzig University, speaks on the importance of MDS World Awareness Day. Dr. Garcia-Manero said he hopes to find “better treatments” and even “one day a cure for this condition.” Across the entire study population, the two most frequent U2AF1 variants were S34F (n=97) and Q157P (n=46). The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations. The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics. The panel discusses optimal dosing for teclistamab. Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab. The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm. The panel continues the conversation around toxicity management for bispecific agents. The panel compares clinical trial and real-world data for CAR-Ts. The panel discusses treatment-related side effects such as CRS, ICANS, and more. Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients. Nitin Jain, MD, joins Chadi Nabhan, MD, MBA, FACP, Host of The HemOnc Pulse, to discuss unmet needs in CLL. The panel addresses side effects that are commonly seen in patients receiving bispecifics. The panel discusses their personal experience with bispecifics-related REMS programs. The panel discusses which patients may not be suitable for CAR T-cell therapy. The panel discusses where they think bispecifics have "the best role" in the myeloma treatment paradigm.